Company intelligence / Profile preview
Nordic Pharma
Hoofddorp, North Holland, Netherlandsnordicpharma.com ↗
- Ownership
- Private
- Employees
- ~240
- Development stage
- Commercial
01
Overview
Nordic Pharma has a portfolio of both proprietary and in-licensed products across several specialty therapeutic areas including women’s health, rheumatology, ophthalmology and critical care. Recent clinical milestones include CE Mark approval for Lacrifill® Canalicular Gel for dry eye disease in Europe as of April 2025[6]. The company continues to expand its international presence with launches of new generics and specialty medicines.
- Therapeutic areas
- Women's HealthOphthalmologyHematologyRheumatology
- Modalities
- Small moleculesgenericsproprietary drugsmedical devices
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Development & supply chain partners globally; specific names not disclosed but includes licensing/acquisition deals for niche hospital/orphan products
Beyond the preview
Go deeper on Nordic Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nordic Pharma.